# Myriad Genetics Inc (MYGN) insider trading

> In the 12 months to Nov 10, 2026, one MYGN insider reported open-market sales of $66.8K across 1 filing; 3 insiders bought $722.2K.

Canonical: https://massive.com/quote/mygn/insider-trading
Latest filing: 2026-11-09 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $66.8K | 1 filing · 1 insider |
| Open-market purchases | $722.2K | 3 filings |
| Pre-arranged sales (10b5-1) | 1 of 1 | All $66.8K sold was pre-arranged |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| S. Louise Phanstiel | Director | — | $494.7K | 1 | — | 2026-02-27 |
| Samraat S. Raha | President and CEO | — | $199.8K | 1 | — | 2026-03-09 |
| Rashmi Kumar | Director | $66.8K | — | 1 | 100% of sales | 2026-06-09 |
| Paul Bisaro | Director | — | $27.6K | 1 | — | 2026-05-14 |

## Open-market trades by filing

4 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-06-09 | 2026-06-08 | Rashmi Kumar | Director | Sale (10b5-1) | 15,000 | $4.46 | $66.8K | 171,889 | — |
| 2026-05-14 | 2026-05-14 | Paul Bisaro | Director | Purchase | 7,500 | $3.69 | $27.6K | 97,441 | — |
| 2026-03-09 | 2026-03-09 | Samraat S. Raha | President and CEO | Purchase | 40,000 | $5.00 | $199.8K | 493,104 | — |
| 2026-02-27 | 2026-02-25 | S. Louise Phanstiel | Director | Purchase | 104,507 | $4.73 | $494.7K | 281,951 | — |

## Other insider activity (not market trades)

- Tax withholding: 34 records
- Grants and awards: 24 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has Myriad Genetics Inc's CEO sold stock?

No. Samraat S. Raha (CEO) made no open-market sales filed as CEO in the last 12 months.

### How current is MYGN’s insider data?

These are MYGN Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The MYGN Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=MYGN&filing_date.gte=2025-11-10&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Myriad Genetics Inc (MYGN) stock price](https://massive.com/quote/mygn.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms